Authors: Kristel S. Knudsen, Sverre Lehmann, Rune Nielsen, Solveig Tangedal, Andreu Paytuvi-Gallart, Walter Sanseverino, Einar M. H. Martinsen, Pieter S. Hiemstra, Tomas M. Eagan


  • Department of Clinical Science, University of Bergen, Bergen, Norway
  • Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway
  • Sequentia Biotech SL, Barcelona, Spain
  • Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands

Publication: Springer Link

Date: October, 2022

Link: The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis


The role of the pulmonary microbiome in sarcoidosis is unknown. The objectives of this study were the following: (1) examine whether the pulmonary fungal and bacterial microbiota differed in patients with sarcoidosis compared with controls; (2) examine whether there was an association between the microbiota and levels of the antimicrobial peptides (AMPs) in protected bronchoalveolar lavage (PBAL).

Thirty-five sarcoidosis patients and 35 healthy controls underwent bronchoscopy and were sampled with oral wash (OW), protected BAL (PBAL), and left protected sterile brushes (LPSB). The fungal ITS1 region and the V3V4 region of the bacterial 16S rRNA gene were sequenced. Bioinformatic analyses were performed with QIIME 2. The AMPs secretory leucocyte protease inhibitor (SLPI) and human beta defensins 1 and 2 (hBD-1 and hBD-2), were measured in PBAL by enzyme-linked immunosorbent assay (ELISA).

The pulmonary fungal and bacterial microbiota in sarcoidosis differed from in controls. Lower antimicrobial peptides levels were seen in sarcoidosis, indicating an interaction between the microbiota and the innate immune system. Whether this dysbiosis represents a pathogenic mechanism in sarcoidosis needs to be confirmed in experimental studies.